Navigation Links
Verified Clinical Trials Will Exhibit at the Annual 2013 SCOPE Summit to Discuss the Professional Research Subject and the Clinical Trial Database Registry

Miami, Fla. (PRWEB) January 08, 2013

Verified Clinical Trials (VCT) will be an exhibitor at the the 2013 Annual SCOPE Summit. While at the conference, Verified Clinical Trials will demonstrate the sophisticated system that it has developed to stop potential professional research subjects from dual enrolling in multiple clinical trials.

Dr. Mitchell Efros, plans to review many of the added features that VCT now offers. These include automatic visit reminders as well as the new dosing reminder to enhance dosing compliance.
"All of these features are of great benefit to both the pharmaceutical company as well as the CRO and research site," added Dr. Efros. These value added features improve the overall experience by saving time and monies.

Mitchell Efros MD FACS, CEO of Verified Clinical Trials (VCT), will describe methods to detect professional research subjects and dual enrollment by use of the unified global clinical trial database registry that VCT offers as a means to discover these individuals and improve clinical trial research subject safety and data quality. Verified Clinical Trials (VCT) is the largest North American clinical trials database registry. Because VCT is 100% web based, the system is scalable and affordable without the need to purchase and install software or hardware. This allows VCT to focus on both early phase and late phase trials improving the coverage and worth of the entire database. Coverage with the VCT database system includes large research facilities and thousands of smaller sites involved in later phase trials as well.

Mitchell Efros MD FACS, the President and CEO of VCT, stated, "We are overwhelmed by the growth Verified Clinical Trials has achieved as well as the recognition by the clinical trial and pharmaceutical industry. We attribute this to the fantastic system we created as well the industry's unwillingness to accept less than perfect data and any potential safety risks to the volunteer."

Kerri Weingard ANP COO added, "We continue to attract and partner with the world's largest and most prominent pharmaceutical and clinical research companies. Our growth has been truly remarkable. This is a direct result of how well our system functions as well as the excellent customer service that VCT provides."

About Verified Clinical Trials
Verified Clinical Trials was developed by experts in the clinical research community to proactively improve research subject safety and data quality in clinical research trials. Verified Clinical Trials halts dual enrollment in clinical trials and defines itself as the world's leader in the field of clinical trial database registries in clinical trial research. Verified Clinical Trials is the only clinical research database registry that is fully web based and designed specifically to enhance the quality of both early and late phase trials and has the scalability to reach all sites nationally and globally. Verified Clinical Trials is a HIPAA- and 21 CFR part 11- compliant online subject registry to anonymously and securely validate subjects and prevent dual enrollment in multiple concurrent research studies. Verified Clinical Trials offers numerous other value-added services to the clinical research site, CRO, and pharmaceutical sponsor, that prove invaluable with regards to financial and legal issues and liabilities. To RSVP or for more information, visit

Verified Clinical Trials Contact Info
Kerri Weingard, ANP, Chief Operating Officer
Verified Clinical Trials +1 516 998-7499

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
2. Research Volunteer Registry from Verified Clinical Trials Adopted by ICON
3. WCCT Global (WCCT) & Verified Clinical Trials (VCT) Announce Medication Adherence Documentation Capabilities Have Been Added to the VCT Clinical Trials Database Registry
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Positive Clinical Study Results for BSPs HyperQ Technology
6. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
7. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
8. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
9. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
10. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The Academy ... Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the ... last few years. Many AMA members have embraced this type of racing and several ...
Breaking Biology Technology:
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/23/2015)... -- Research and Markets ( ) has announced ... Market 2015-2019" report to their offering. ... voice recognition biometrics market to grow at a CAGR ... --> The report, Global Voice Recognition ... in-depth market analysis with inputs from industry experts. The ...
(Date:10/22/2015)... Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), a leading ... first quarter ended September 30, 2015. --> ... fiscal 2016 grew 66 percent over the comparable quarter last year ... 2016 was $23.8 million, or $0.62 per diluted share. ... the first quarter of fiscal 2016 grew 39 percent over the ...
Breaking Biology News(10 mins):